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Abstract Heat shock protein 90 (Hsp90) facilitates mat-
uration and stability of HER2. Combining an Hsp90
inhibitor and trastuzumab has demonstrated anti-tumor
effects in patients with HER2? breast cancer. Adults with
measurable, locally advanced or metastatic HER2? breast
cancer and prior trastuzumab treatment were enrolled in a
phase 2 trial employing weekly 300 mg/m2 retaspimycin
HCl, a potent Hsp90 inhibitor, with 6 mg/kg trastuzumab
every 3 weeks. A Simon’s two-stage design determined
trial expansion by dose-limiting toxicity (DLT) and
response rates. Pharmacokinetics and electrocardiograms
were evaluated. Twenty-six patients with median age
52.5 years (range 33–72) enrolled with a median of six
prior chemotherapeutic regimens (range 2–20). On study,
patients received a median of three treatment cycles (range
1–12). No DLTs were observed. Most adverse events
(AEs) were grade 1 or 2; common treatment-related AEs
included fatigue (46 %), nausea (31 %), and diarrhea
(23 %). One patient had treatment-related serious AEs of
grade 1 diarrhea and grade 3 hypokalemia. grade 3 trans-
aminase elevation occurred in one patient (4 %) who also
had metastatic liver disease. Sixteen patients (62 %) had
stable disease, with a median on-study duration of
2.4 months (range 1.1–8.2). No confirmed responses were
observed. Retaspimycin HCl at 300 mg/m2 weekly in
combination with trastuzumab was well tolerated and
without significant toxicities. Modest clinical activity was
observed, but did not meet criteria for trial expansion. The
safety profile for patients on study raises the possibility of
retaspimycin HCl underdosing that limited efficacy. Stud-
ies employing higher doses are ongoing.
Keywords Phase 2  Retaspimycin plus trastuzumab 
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Introduction
Preclinical models and clinical studies in patients with
advanced HER2? disease have shown that trastuzumab-
refractory HER2? breast cancer is susceptible to the
effects of Heat shock protein 90 (Hsp90) inhibition [1, 2].
This effect is mediated by Hsp90 inhibition-induced HER2
degradation and, additionally, via effects on component
proteins of the PI3 k-Akt pathway, p95, and HER3, all of
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which are implicated in the development of trastuzumab
resistance [3, 4].
The most promising activity to date has been observed
with tanespimycin (17AAG; KOS953), a geldanamycin
analog, when given in combination with trastuzumab to
HER2? patients pre-treated and progressing on trast-
uzumab therapy [2, 5]. In spite of this activity, the clinical
development of tanespimycin was suspended in 2010 by
the sponsor and all trials with this drug have closed.
Retaspimycin hydrochloride (HCl) is an Hsp90 inhibitor
designed to preserve the structural complexity of the natural
parent compound while overcoming the limitations of ear-
lier ansamycins. Because of the better aqueous solubility of
retaspimycin HCl, it emerged as a potential replacement for
tanespimycin. In the circulation, retaspimycin HCl is
deprotonated and the free base hydroquinone is oxidized to
17-AAG; 17-AAG is subsequently reduced back to the
hydroquinone by cellular reductase enzymes, such that the
two moieties exist in a dynamic equilibrium in vivo.
In pre-clinical studies, retaspimycin HCl has shown
promising activity in multiple models of solid and hema-
tologic malignancies [6–9]. Specifically, retaspimycin HCl
markedly reduced total levels of HER2 and Akt, as well as
phosphorylated Akt and MAPK to an equal extent in
trastuzumab-sensitive and trastuzumab-resistant cells.
When administered either as a single agent or in combi-
nation with trastuzumab, retaspimycin HCl also inhibited
in vivo the growth of both trastuzumab-sensitive and
trastuzumab-resistant tumor xenografts.
Based on these pre-clinical results, and using doses
identified in phase 1 clinical trials of retaspimycin HCl
monotherapy, a phase 2 clinical trial was initiated to
evaluate the efficacy of retaspimycin HCl plus trastuzumab
in patients with advanced HER2? metastatic breast cancer
progressing on prior trastuzumab therapy.
Patients and methods
Patients
Adult patients (C18 years of age) with pathologically
confirmed locally advanced or metastatic breast cancer and
one or more measurable lesions according to response
evaluation criteria in solid tumors (RECIST) were enrolled.
All patients were required to have HER2- expressing
primary or metastatic tumors defined as either a 3? score
by immunohistochemistry or amplification on a fluores-
cence in situ hybridization assay. Patients must have
received at least two prior regimens in the advanced setting
containing a HER2- targeted agent. Trastuzumab must
have been a component of at least one of these regimens.
There was no upper limit to the number of prior therapies
patients may have received, although patients must have
had disease progression during or since their most recent
systemic therapy. Additional eligibility criteria included a
left ventricular ejection fraction within the normal limits
and adequate baseline organ and marrow function, specif-
ically a bilirubin within normal limits and alanine amino-
transferase and aspartate aminotransferase B1.59 upper
limit of normal (ULN).
Key exclusion criteria included prior treatment with any
Hsp90 inhibitor, prior significant intolerability or adverse
events (AEs) related to trastuzumab (including infusion
reactions or heart failure), baseline QTc [470 ms, sinus
bradycardia, or other significant co-morbidity within the
previous 6 months that may have put the patient at undue
risk during the study. Patients were also ineligible if they
had a recent history (within 3 months) of active keratitis or
keratoconjunctivitis, clinically active brain metastases,
prior hepatic resections or hepatic-directed therapies, or
had used medication or food that was a clinically relevant
CYP3A inhibitor or inducer within 2 weeks prior to the
first dose of study treatment.
All patients provided written informed consent. The
study was approved by local institutional review boards
and conducted in accordance with good clinical practice
guidelines and the declaration of Helsinki.
Study design and assessments
This prospective, multicenter, phase 2 trial commenced in
2009. Patients were scheduled to receive retaspimycin HCl
at a dose of 300 mg/m2 once or twice weekly plus trast-
uzumab. Patients on the twice weekly schedule received
retaspimycin HCl for 2 weeks followed by 1 week off
treatment. Patients on the once weekly schedule did not have
an off-treatment period. After three patients enrolled on the
twice weekly regimen, this schedule was closed to accrual
and all new patients were enrolled at a dose of 300 mg/m2
once weekly, based upon findings in other concurrent
studies with retaspimycin HCl wherein imbalanced mor-
tality, regardless of causality, compared to placebo was
observed at doses given twice weekly. Discussion of safety
and efficacy is limited to the 26 patients who received
treatment on the once weekly regimen, because this larger
study population generated more meaningful results than the
study population that received twice weekly dosing (n = 3).
Evaluable patients were defined as patients who either
completed Cycle 1 or had a dose-limiting toxicity in Cycle
1, where completion of Cycle 1 was defined for the once
weekly schedule as receiving one dose of trastuzumab and
at least two doses of retaspimycin HCl. For the twice
weekly schedule, completion of Cycle 1 was defined as
receiving one dose of trastuzumab and at least three doses
of retaspimycin HCl. The study was designed to pause
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between stages to complete safety and efficacy analyses.
All patients received conventional trastuzumab every
3 weeks as an intravenous infusion of 6 mg/kg, with an
8 mg/kg initial loading dose for patients whose last trast-
uzumab therapy was [4 weeks prior to study entry. On
days where both drugs were given together, trastuzumab
was administered first.
The primary endpoints were the overall response rate
(ORR), as defined by RECIST 1.1 and the evaluation safety
and tolerability. Secondary endpoints included progres-
sion-free survival (PFS), time to treatment progression
(TTP), overall survival (OS) and pharmacokinetics (PK).
Exploratory endpoints were time to first response, duration
of response, and clinical benefit consisting of a composite
of complete response, partial response, tumor regression of
20–29 %, and stable disease C 6 months).
Assessments and data collection
Tumor assessments and echo/multi-gated acquisition scans
were made at baseline and after every two cycles
(6 weeks). An independent radiographic tumor assessment
with two reviewers and one adjudicator was performed in
addition to local assessments. Electrocardiograms were
taken at baseline and in triplicate pre- and post-infusion on
day 1 of Cycles 1, 3, and 5. The NCI common terminology
criteria for adverse events version 3.0 was used to grade
toxicities during the trial. Given the hepatotoxicity reported
in a previous study in patients with gastrointestinal stromal
tumors (GIST), liver function tests (AST, ALT, total bili-
rubin, and alkaline phosphatase) were drawn and reviewed
within 24 h prior to each dose of retaspimycin HCl. Delays
and/or modifications in dose were implemented for
increases in liver function test levels Cgrade 2. An oph-
thalmologic exam was conducted at baseline for all patients
and, as needed, while patients were on study.
Dose-limiting toxicities were defined as any of the fol-
lowing events occurring during the first cycle of treatment
that were attributable to the study regimen: death related to
investigational regimen; grade 4 neutropenia lasting
C5 days; grade C 3 febrile neutropenia with elevated
temperature (C101.5 F) on two occasions; grade 4
thrombocytopenia or anemia; grade C 3 AST, ALT,
alkaline phosphatase or total bilirubin at any time; grade 2
AST, ALT, or total bilirubin occurring within 24 h prior to
retaspimycin HCl infusion; grade C 3 diarrhea, nausea, or
vomiting despite optimal medical therapy; grade C 3 QTc
prolongation; and, any non-hematological toxicity of
Cgrade 3, except for asymptomatic lipase increases in the
absence of clinical signs and symptoms of pancreatitis.
Blood samples for the main PK analyses were collected
pre- and post-trastuzumab and pre- and post-retaspimycin
HCl, as well as 30 min, 1, 2, 3, 5, and 24 h after dose 1
retaspimycin HCl during Cycle 1 and dose 4 of Cycle 1 for
the twice weekly schedule. Additional samples at a variety of
pre-specified time points during Stage 1 were also collected.
Statistical assessments
A Simon’s 2-stage optimal design was implemented within
each treatment schedule with the assumed response rate for
the null hypothesis of po = 11 %, the assumed response
rate for the alternative hypothesis of p1 = 24 %, a targeted
one-sided alpha = 0.05, and power = 80 %. If \2/20
patients achieved a response (PR or CR per RECIST 1.1)
using a central independent radiology review in Stage 1,
then the treatment would be deemed futile and no addi-
tional patients would be enrolled into Stage 2 for that
treatment schedule. For either schedule, if criteria were met
to proceed to Stage 2, then *26 additional patients would
be added to that treatment schedule and if 9 or more of the
total 46 patients achieved a response, then the study would
be considered successful.
Efficacy and safety analyses were conducted on the 26
patients who received treatment on the once weekly regi-
men, because analysis of this larger study population
(n = 26) generated more statistically meaningful results
than the study population that received twice weekly dos-
ing (n = 3). Pharmacokinetic analyses were conducted on
all patients with available data in the once weekly treat-
ment regimen (n = 24) and twice weekly treatment regi-
men (n = 3). Patients who discontinued the study without
any post-baseline disease evaluation were considered
treatment failures. All efficacy analyses were to be per-
formed for each treatment schedule separately.
Progression-free survival (PFS) defined as time to death
or progression, TTP, and OS were calculated from start of
treatment. Pharmacokinetic parameters based on the actual
sample collection times were determined using standard
noncompartmental methods. The PK parameters assessed
included: Cmax, Tmax, AUC?, T1/2, CL, and Vss.
Plasma retaspimycin, 17-AAG, 17-AG, and trastuzumab
concentration data and all derived PK parameters were
summarized using descriptive statistics including N, mean,
median, standard deviation, geometric mean, coefficient of
variance, and minimum and maximum.
Results
Patients
Initially, three patients were enrolled to receive 300 mg/m2
retaspimycin HCl on the twice weekly regimen. Based on
toxicity findings from another ongoing trial of retaspimycin
HCl, this schedule was closed to further accrual and all
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subsequently enrolled patients received 300 mg/m2 retas-
pimycin HCl on the once weekly regimen (see study design
and assessments). Results are presented for the 26 patients
(25 females and 1 male) who received retaspimycin HCl on
the once weekly regimen.
Overall, study patients (N = 26) were heavily pre-trea-
ted prior to entering the study. Median duration of trast-
uzumab therapy was 33 months (range 10–104 months),
and patients had been exposed to a median of 6 prior
chemotherapy regimens for breast cancer (range 2–26
regimens). Other baseline characteristics are presented in
Table 1. All patients discontinued from the study for either
radiographic or clinical disease progression (n = 22, 85 %)
or an adverse event (n = 3, 12 %), with only one patient
discontinuing for an unspecified reason.
Study treatment
Among patients who received 300 mg/m2 retaspimycin
HCl once weekly (N = 26), the median number of treat-
ment cycles initiated was three (range, 2–12 cycles) and the
median number of doses of retaspimycin HCl was 7.5
(range, 4–35 doses). The median number of doses of
trastuzumab (6 mg/kg every 3 weeks) was three (range,
2–11 doses). Overall, the median number of days on study
therapy was 48 (range, 23–246 days).
Efficacy
In this heavily pre-treated population, the best response
observed was stable disease in 16 patients (62 %),
including one patient with prolonged ([6 months) stable
disease (Figs. 1, 2). Patients who had stable disease
received a median of *4 cycles of treatment (range, 2–12
cycles), with a median of *2.4 months on study (range,
1.1–8.2 months) (Fig. 2). Of the 26 patients enrolled to
receive weekly dosing, 22 patients had measurable disease
according to central review. Tumor shrinkage and best
response in this group as determined by an independent
radiographic assessment with 2 reviewers and one adjudi-
cator (as needed) is provided in Fig. 1.
Safety and tolerability
The adverse events occurring in C5 % of patients attrib-
utable to the study treatment (retaspimycin HCL, trast-
uzumab, or both) are summarized in Table 2. Overall, the
most common toxicities were fatigue (46 %), nausea
Table 1 Baseline patient characteristics
Characteristic Result
Total enrolled, n 26
Age (years)a 53 (33–72)
Females, n (%) 25 (96)
Time since initial diagnosis of breast cancer (months)a 72 (20–179)
Duration of prior trastuzumab (months)a 33 (10–104)
Number of prior chemotherapy regimens for MBCa 6 (2–6)
Patients assayed for CTC at baseline, n 24
Patients with detectable CTC at baseline, n (%) 20 (83)
CTCs at baselinea 3.5 (0–29)
Patients with CTC samples assayed for HER2 by
FISH, n
7
HER2 amplification detected in CTC, n (%) 7 (100)
a Median (range)
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Patients (N = 22)
Fig. 1 Best %-change in target lesion size. 22 patients had measur-
able disease according to central review, 15 (68 %) with best response
of stable disease. Two patients with decreases in target lesion size














Best Response on Study
Fig. 2 Time on study. Patients who had stable disease received a
median of*4 cycles of treatment (range, 2–12 cycles), with a median
of *2.4 months on study (range, 1.1–8.2 months)
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(31 %), discolored urine (23 %), and diarrhea (23 %),
mostly with CTCAE severity grades of 1 or 2. Two fatal-
ities that were attributed to underlying disease and unre-
lated to either study treatment involved events of
pneumonia and respiratory failure in one patient and
bronchoaspiration in the second patient. Serious, related
treatment-emergent AEs of grade 1 diarrhea and resulting
grade 3 hypokalemia occurred in one patient. The events
resolved with medical therapy and did not recur on
rechallenge at 225 mg/m2 once weekly. Three patients
required dose reductions due to gastrointestinal toxicity.
Three additional patients discontinued therapy for treat-
ment-related AEs: grade 2 decrease in left ventricular
ejection fraction (n = 1), grade 3 increase in serum lipase
(n = 1), and grade 3 increases in ALT, AST, and gamma-
glutamyl transpeptidase in 1 patient with liver metastases,
whose ALT and AST levels recovered to grade 2 by
30 days after discontinuing study treatment. For the
majority of patients, liver enzymes remained at levels
observed at baseline, whether normal or elevated. There
were no cases of symptomatic ocular toxicity.
Electrocardiogram
The median baseline QTc interval using fridericia’s cor-
rection formula (QTcF) was 401.7 ms (range, 351–464).
The median first post-baseline QTcF was 402.0 ms (range,
364–475), representing a median change from baseline of
3.8 ms (range, 15–34); the last ‘‘on treatment’’ median
QTcF was 417.8 ms (range, 368–475), representing a
median change of 7.5 ms (range, -14–55). The minimum
and maximum values for any patient at any post-treatment
time point were 364 and 475 ms, respectively. Seven
(27 %) patients with normal QTcF durations at baseline
had post-baseline QTcF durations [450 ms or that
increased[30 ms from baseline. Overall, the QTcF values
fluctuated within a narrow range, remaining Bgrade 2 at all
times.
Pharmacokinetics
Plasma samples were analyzed for retaspimycin and its
metabolites, 17-AAG, and 17-AG, and were available from
24 patients who received retaspimycin HCI once weekly
and from 3 patients on the twice weekly regimen. Plasma
concentrations for retaspimycin, 17-AAG, and 17-AG
following administration of retaspimycin HCI once or
twice weekly were similar. On Cycle 1 dose 1, the overall
mean exposures (AUC0-?) to retaspimycin, 17-AAG, and
17-AG were 10,003, 15,334, and 22,975 ng h/mL,
respectively. On Cycle 4 dose 1, AUC0-? values for ret-
aspimycin, 17-AAG, and 17-AG were 6,714, 14,337, and
17,261 ng h/mL, respectively. There was significant inter-
patient variability in Cmax and AUC0-? across all ana-
lytes evaluated, with coefficient of variation (%CV) values
ranging from 39 to 103 %. Exposure to 17-AG (which has
similar potency to retaspimycin HCl in cellular assays)
accounted for *50 % of the total exposure to drug, cal-
culated as the aggregate AUC of parent drug plus the two
metabolites. The mean apparent terminal elimination half-
lives for retaspimycin, 17-AAG, and 17-AG were 2.86,
4.86, and 4.57 h after single dose administration, and 3.40,
4.33, and 4.63 h following administration of repeated
doses. Systemic clearance of retaspimycin averaged 106.5
and 94.9 L/h, on Cycle 1 day 1 and Cycle 1 day 4,
respectively; however, notable variability was observed
(%CV of 133 and 72). The clearance and half-life estimates
obtained in this study are similar to data presented previ-
ously [10] for retaspimycin HCI. Overall, the PK param-
eters after repeat doses of retaspimycin HCI in the presence
of trastuzumab on Cycle 4 dose 1 were similar to those
observed after the first dose without trastuzumab on Cycle
1 dose 1.
Blood samples were collected for determination of
trastuzumab pharmacokinetics in Cycle 4 (N = 11). Mean
trastuzumab serum concentrations peaked at the end of the
90 min infusion and remained fairly flat through the first
24 h following infusion. Concentrations declined slowly
thereafter, with detectable concentrations (lower limit of
Table 2 Treatment-relateda adverse events seen in C5 % of patients
Adverse events Worst CTCAE grade on study,
n (%)
1 or 2 3 4
Fatigue 12 (46) 0 (0) 0 (0)
Nausea 7 (27) 1 (4) 0 (0)
Diarrhea 5 (19) 1 (4) 0 (0)
Discolored urine 6 (23) 0 (0) 0 (0)
Asthenia 4 (15) 0 (0) 0 (0)
Increased alkaline phosphatase 4 (15) 0 (0) 0 (0)
Anorexia 4 (15) 0 (0) 0 (0)
Headache 4 (15) 0 (0) 0 (0)
Pyrexia 3 (12) 0 (0) 0 (0)
Chills 2 (8) 0 (0) 0 (0)
Abdominal pain 2 (8) 0 (0) 0 (0)
Constipation 2 (8) 0 (0) 0 (0)
Vomiting 1 (4) 1 (4) 0 (0)
Increased ALT 1 (4) 1 (4) 0 (0)
Increased AST 1 (4) 1 (4) 0 (0)
Increased amylase 2 (8) 0 (0) 0 (0)
Decreased ejection fraction 2 (8) 0 (0) 0 (0)
Exertional dyspnea 2 (8) 0 (0) 0 (0)
First degree AV block 2 (8) 0 (0) 0 (0)
a Related to retaspimycin HCl, trastuzumab, or both
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the bioanalytical assay = 10 lg/mL) in 6 of 6 patients who
had samples collected 2 weeks after the infusion and in
4 of 5 patients who had samples collected 3 weeks
after infusion. In Cycle 4, the mean trastuzumab exposure
over the 24 h following dose administration was
3,094 lg*h/mL, which increased to a mean concentration
of 17,322 lg*h/mL over the 3-week sampling interval.
Mean systemic clearance and volume of distribution were
low, estimated as 20.2 ± 7.2 mL/h and 3.9 ± 0.59 L,
respectively. Based on the sampling scheme employed in
this study, the mean apparent terminal elimination half-life
was 154 h. It has been previously reported that sampling
within a single dosing interval underestimates the terminal
half live of trastuzumab [11]. This is supported by a ter-
minal half-life estimate of 28.5 days obtained using
population PK methods [12]. Direct comparison of trast-
uzumab PK profiles across clinical studies is challenging
due to disparate patient populations, varying sample col-
lection schedules and different PK analysis methods;
however, the pharmacokinetics of trastuzumab in this
combination regimen are within the range of data described
in the literature [11, 13, 14].
Discussion
In previous breast cancer models in the treatment of
HER2?, the combination of an Hsp90 inhibitor plus trast-
uzumab showed synergistic anticancer activity; this trans-
lated clinically to an ORR of 22 % and CBR of 59 % for
tanespimycin (17AAG) plus trastuzumab in patients with
trastuzumab-refractory disease. Despite the promise of these
earlier results, the current trial in patients with HER2?
breast cancer did not meet the pre-specified expansion cri-
teria for the combination of retaspimycin HCl plus trast-
uzumab. In view of PK data that show retaspimycin HCl is
capable of interconversion to 17AAG in vivo, the findings
from this trial are unexpected and raise important questions
regarding the development of this inhibitor.
An important finding from this trial is an apparent lack
of moderate or severe toxicity. While the observed favor-
able toxicity profile of retaspimycin HCl in this trial was
supported by low rates of expected drug-related AEs, in
this case, the toxicity rates might suggest that an insuffi-
cient dose of study drug was administered to adequately
treat disease. The original planned dose of retaspimycin
HCl for the study was 300 mg/m2 twice weekly for 2 of
3 weeks, which was lower than the twice weekly dose used
in the phase 1 study (400 mg/m2) in patients with GIST. In
that phase 1 study, investigators reported metabolic
responses in patients with refractory GIST. This same
schedule was then chosen for the follow-up phase 3 ran-
domized GIST trial; however, an imbalance in deaths in the
retaspimycin HCl arm compared to the placebo arm
resulted in a decision to modify the retaspimycin HCl dose
for the present trial in breast cancer to 300 mg/m2 weekly.
By comparison, the recommended phase 2 dose for tanes-
pimycin in combination with trastuzumab for the same
patient population was 450 mg/m2 weekly, a dose that was
also below the MTD, but that was felt to be clinically
optimal because it produced tumor responses and was well
tolerated. While the decision to decrease the dose in the
present breast cancer trial was a necessary and appropriate
action to preclude potential toxicity, the magnitude of the
reduction for a breast cancer population may have been too
large. Unlike the GIST population, where liver metastases
can be more extensive and are often treated with site-spe-
cific therapies, including surgical liver resections and
hepatic arterial chemo-embolization, patients with meta-
static breast cancer are largely treated with systemic ther-
apies and, as such, have a greater baseline liver reserve.
Indeed, only one patient on the present breast cancer trial
developed greater than a grade 1 liver enzyme elevation.
Similarly, a comparison of other toxicities between the
present breast cancer trial and that of the tanespimy-
cin ? trastuzumab trial, reveals an almost twofold increase
in the incidence of toxicities seen with tanespimycin
compared to retaspimycin HCl, the vast majority of which
were grades 1 and 2. Overall, the absence of toxicities
combined with a large number of patients with short-lived
stable disease, suggests that the combination of retaspi-
mycin HCl plus trastuzumab is active but, perhaps, was not
optimally delivered in this trial.
Other ongoing trials with retaspimycin HCl are exam-
ining novel combinations in patients with advanced non-
small cell lung cancer (NSCLC), where mutated EGFR,
Kras and the EML4-ALK fusion protein are known sensi-
tive clients of HSP90. In a phase 1b trial, retaspimycin HCl
and docetaxel administered both weekly and on a 3 week
schedule did not reveal an MTD. An expansion phase of
this trial has tested retaspimycin HCl 300 mg/m2 with
docetaxel given weekly with positive safety results. Results
from this study led to an ongoing phase 2 evaluation of
450 mg/m2 retaspimycin HCl administered weekly in
combination with 75 mg/m2 docetaxel administered every
3 weeks in patients with advance NSCLC. In addition, a
phase 1 dose escalation study of retaspimycin HCl with
everolimus is underway in patients with advanced NSCLC.
Second generation non-ansamycin Hsp90 inhibitors
including NVP- AUY922, STA-9090/ganetespib, ATI-
13387, and PU-H71, among others, are also undergoing
clinical evaluation. Initial results in breast cancer, as well
as other cancer types, reveal evidence of antitumor effects
and the potential for an improved therapeutic index. Hence,
further studies of these agents as monotherapy and in novel
combinations are also planned.
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Based on the results from this study, a trial in patients
with HER2? breast cancer utilizing a higher dose of ret-
aspimycin HCl is warranted. Further, the advantages in
formulation, and hence a therapeutic index with this Hsp90
inhibitor that maximizes activity and minimizes toxicity,
were insufficiently tested in the current study. As is evident
from prior experience and emerging patterns of drug
development, any future trial must incorporate tumor
biopsies or novel methods to evaluate pharmacodynamic
endpoints to guide patient and dose selection with Hsp90
inhibitor therapy. Earlier Hsp90 inhibitors were not able to
achieve an acceptable therapeutic index as their clinical
development was hindered by toxicity and formulation
issues. While the initial reports with the inhibitors currently
in development are encouraging, the optimal use of these
agents will depend upon a full understanding of the com-
plex role of Hsp90 in both normal and cancer cell
physiology.
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